Details of the Drug

General Information of Drug (ID: DM1WXA6)

Drug Name

Lofexidine

Synonyms

Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole

Indication

Disease Entry	ICD 11	Status	REF
Heroin and opiate withdrawal	6C43	Approved	[1]
Opioid dependence	6C43.2Z	Approved	[2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

259.13

Topological Polar Surface Area (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 46 mcgh/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 85% [3]
Clearance: The clearance of drug is 17.6 L/h [5]
Elimination: The elimination of lofexidine is primarily through the renal system and it represents 94% of the administered dose while elimination in feces corresponds to only 0.93% [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 11 hours [7]
Metabolism: The drug is metabolized via the CYP2D6 and in a minor degree by CYP1A2 and CYP2C19 [8]
Vd: The volume of distribution (Vd) of drug is 300 L [5]

Chemical Identifiers

Formula: C11H12Cl2N2O
IUPAC Name: 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
Canonical SMILES: CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl
InChI: InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
InChIKey: KSMAGQUYOIHWFS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 30668
ChEBI ID: CHEBI:51368
CAS Number: 31036-80-3
DrugBank ID: DB04948
TTD ID: D0K0MW
INTEDE ID: DR0967
ACDINA ID: D01217

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[9], [1]
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lofexidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[61]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Midostaurin.	Acute myeloid leukaemia [2A60]	[62]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Arn-509.	Acute myeloid leukaemia [2A60]	[63]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[64]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Ivabradine.	Angina pectoris [BA40]	[63]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[65]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Levalbuterol.	Asthma [CA23]	[66]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Retigabine.	Behcet disease [4A62]	[62]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Eribulin.	Breast cancer [2C60-2C6Y]	[62]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Bosutinib.	Breast cancer [2C60-2C6Y]	[62]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[67]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[68]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[66]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[68]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Pasireotide.	Cushing syndrome [5A70]	[62]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Osilodrostat.	Cushing syndrome [5A70]	[63]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Lofexidine and OPC-34712.	Depression [6A70-6A7Z]	[69]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Lofexidine and Esketamine.	Depression [6A70-6A7Z]	[70]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Ingrezza.	Dystonic disorder [8A02]	[62]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[71]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[62]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Lofexidine and ITI-007.	Insomnia [7A00-7A0Z]	[69]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[63]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Crizotinib.	Lung cancer [2C25]	[72]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Ceritinib.	Lung cancer [2C25]	[62]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Osimertinib.	Lung cancer [2C25]	[73]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Lumefantrine.	Malaria [1F40-1F45]	[70]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[63]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Vemurafenib.	Melanoma [2C30]	[62]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Lofexidine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[74]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Lofexidine and Lasmiditan.	Migraine [8A80]	[75]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Panobinostat.	Multiple myeloma [2A83]	[76]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Siponimod.	Multiple sclerosis [8A40]	[70]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Fingolimod.	Multiple sclerosis [8A40]	[62]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Lofexidine and Ozanimod.	Multiple sclerosis [8A40]	[77]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Romidepsin.	Mycosis fungoides [2B01]	[62]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Entrectinib.	Non-small cell lung cancer [2C25]	[70]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Rucaparib.	Ovarian cancer [2C73]	[62]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Triclabendazole.	Parasitic worm infestation [1F90]	[62]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Lofexidine and Safinamide.	Parkinsonism [8A00]	[78]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Pimavanserin.	Parkinsonism [8A00]	[79]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[80]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Lefamulin.	Pneumonia [CA40]	[81]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Degarelix.	Prostate cancer [2C82]	[63]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and ABIRATERONE.	Prostate cancer [2C82]	[63]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Enzalutamide.	Prostate cancer [2C82]	[63]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Relugolix.	Prostate cancer [2C82]	[63]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Asenapine.	Schizophrenia [6A20]	[62]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Lofexidine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[62]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[62]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[63]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Pitolisant.	Somnolence [MG42]	[63]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[62]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Lofexidine and Lenvatinib.	Thyroid cancer [2D10]	[62]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Lofexidine and Cabozantinib.	Thyroid cancer [2D10]	[63]
-----------


⏷ Show the Full List of 55 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lofexidine 0.18 mg tablet	0.18 mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend. 2008 Sep 1;97(1-2):158-68.
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	EMA Public Assessment Report: Hepcludex (bulevirtide) powder for injectable solution
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	FDA reports
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
10	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
11	The Drugs.com International Drug Name Database: Lofexidine
12	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
13	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
14	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
15	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
16	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
17	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
20	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
21	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
22	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
26	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
28	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
29	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
30	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
31	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
32	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
33	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
34	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
35	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
36	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
38	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
39	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
40	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
41	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
42	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
43	alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
44	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
45	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
46	A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
47	Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
48	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
49	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
50	alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
51	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
52	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
53	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
54	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
55	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
56	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
57	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
58	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
59	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
60	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
61	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
62	Canadian Pharmacists Association.
63	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
64	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
65	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
66	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
67	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
68	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
69	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
70	Cerner Multum, Inc. "Australian Product Information.".
71	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
72	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
75	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
76	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
77	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
78	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
79	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
80	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
81	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.